In vivo studies using zebrafish and mouse xenograft models further validated its anti-prostate cancer efficacy.<h4>Conclusion</h4>Trichodermamide B targets catalase while mediating crosstalk between the catalase axis and the AR signalling axis to induce oxidative stress and apoptosis in prostate cancer cells. Here, AR is linked to prostate carcinoma.